Literature DB >> 7118558

Is there a risk for kidney stone formation in cystic fibrosis?

H Böhles, D Michalk.   

Abstract

Patients with malabsorption syndromes have an increased risk of kidney stone formation. Those with cystic fibrosis (CF) suffer from extreme forms of steatorrhea, but they are not reported to be prone to kidney stone formation. Risk parameters for renal stone formation were studied in the urine of 43 patients with cystic fibrosis and compared to those of 5 patients with calcium oxalate nephrolithiasis and 21 healthy controls. Patients with CF showed increased urinary concentrations of oxalate, phosphate, xanthine and uric acid, and decreased concentrations of magnesium and citrate, comparable to concentrations found in patients with calcium oxalate stones. However, compared to stone bearing controls the calcium concentration was markedly decreased in the urine of CF patients. Our results suggest that hypocalciuria in CF seems to protect against nephrolithiasis despite the presence of lithogenic factors. Calcium supplementation instituted for clinical reasons may result in an increased risk for kidney stone formation. This risk may be diminished by additional administration of magnesium as well as allopurinol.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7118558

Source DB:  PubMed          Journal:  Helv Paediatr Acta        ISSN: 0018-022X


  6 in total

1.  Oxalate and calcium excretion in cystic fibrosis.

Authors:  M A Turner; D Goldwater; T J David
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

2.  Renal diseases in adults with cystic fibrosis: a 40 year single centre experience.

Authors:  M J Wilcock; A Ruddick; K M Gyi; M E Hodson
Journal:  J Nephrol       Date:  2015-02-25       Impact factor: 3.902

Review 3.  Urolithiasis in children: current medical management.

Authors:  J Laufer; H Boichis
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

Review 4.  Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?

Authors:  Ammon B Peck; Benjamin K Canales; Cuong Q Nguyen
Journal:  Urolithiasis       Date:  2015-12-08       Impact factor: 3.436

5.  Acquired hyperoxaluria and haematuria in children.

Authors:  A Voghenzi; T M Bezzi; P Lusardi; S Soriani
Journal:  Pediatr Nephrol       Date:  1992-07       Impact factor: 3.714

6.  Predisposing factors for nephrolithiasis and nephrocalcinosis in cystic fibrosis.

Authors:  Hamid-Reza Kianifar; Saeedeh Talebi; Mahmoodreza Khazaei; Saeed Talebi; Ali Alamdaran; Simin Hiradfar
Journal:  Iran J Pediatr       Date:  2011-03       Impact factor: 0.364

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.